LGND data by YCharts. While I'm cherry-picking the data to make ... Last year, the millionaire-maker stock generated $71.9 million in total revenue, representing growth of 11% from 2014 and 129% growth from 2012. The unique business …
Stock
Below is a chart showing RAD's trailing twelve month trading history, with the $5 strike highlighted in orange: And Ligand Pharmaceuticals Inc (LGND) options are showing a volume of 1,466 contracts thus far today. That number of contracts …
Shares of Ligand Pharmaceuticals (NASDAQ:LGND), Celldex Therapeutics (NASDAQ ... Let's take a closer look to see if any are right for you. This biotech stock has a lot to like, although a recent price of about 300 times trailing earnings …
The Motley Fool
9.4 months in the Velcade combination, said Evercore analyst John Scotti. Ligand Pharmaceuticals (LGND) stock tanked 12%, to 99.64, hitting a six-month low. Ligand earns royalties on Kyprolis. Tuesday's news is not positive, RBC's Yee …
Multiple myeloma
Ligand Pharmaceuticals (Nasdaq:LGND) hit a new 52-week high Tuesday as it is currently trading at $16.27, above its previous 52-week high of $16.24 with 67,799 shares traded as of 1:59 p.m. ET. Average volume has been 145,900 …
LGND’s 50-day moving average is $117.90 and its two hundred day average is $115.24. The last stock price is down 3.83% relative to the 200-day moving average, compared with the S&P 500 Index which has not moved over the same period. …
Ligand Pharmaceuticals Incorporated LGND reported fourth-quarter 2016 earnings of 50 cents per share (including the impact of stock-based compensation expense), down 11.1% from the year-ago figure. The Ligand stock underperformed …
We take it to the streets as we will sell out from our first collection at Balders biks, Nørrebro, Copenhagen. We will make sure you can make a bargain from our first collection. In the area it will also be possible to listen to summervibes from …
Ligand Pharmaceuticals Incorporated LGND is scheduled to report second-quarter 2016 results on Aug 4 before the market opens. In the last reported quarter, Ligand had posted a positive earnings surprise of 67.39%. Let’s see how things are …
ETFs by nature are passive index-followers, so as long as the stock remains in the index, it doesn't much matter whether analysts find the stock overvalued or undervalued. Below are some of the ETFs that hold LGND at last report: